Glenn J. Hanna

Nov 16, 2023 | jamanetwork.com | Glenn J. Hanna |Alessandro Villa |Herbert Wertheim College

Key PointsQuestion  Can immune checkpoint therapy treat high-risk oral precancerous disease to prevent progression to oral squamous carcinoma?

Oct 27, 2023 | onclive.com | Glenn J. Hanna

Glenn J. Hanna, MD, director, Center for Cancer Therapeutic Innovation (Early Drug Development Program), director, Center for Salivary and Rare Head and Neck Cancers, physician, Dana-Farber Cancer Institute; assistant professor, medicine, Harvard Medical School, discusses the significance of the FDA approval of toripalimab-tpzi (Loqtorzi) for patients with recurrent or metastatic nasopharyngeal carcinoma.